This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
"F our classes of agents have established effectiveness against acute lymphocytic leukemia in children," Emil Frei III, MD, of the National Institute of Health in Bethesda, Md, reported to the 55th annual meeting of the American Association for Cancer Research, Inc., in Chicago, April 9-11. Frei was one of several investigators who reported chemotherapeutic advances in the treatment of many different kinds of cancer. Most told cautiously of remissions in disease of varying duration due to recently developed therapeutic agents or combinations of agents.
Frei, working with E. J. Freireich, MD, and M. Karon, MD, described 17 patients he has treated with a combination called VAMP, which consists of vincristine, amethopterin, 6-mercaptopurine, and prednisone administered simultaneously. "Fourteen patients achieved complete clinical and hematological remission," Frei said, and in 11 patients, who completed the course of treatment and received no further therapy, remission lasted a median of four months. In support
Cancer Investigators Hear of Chemotherapeutic Advances, Protein Test, Carcinogens in City Air. JAMA. 1964;188(4):29–31. doi:10.1001/jama.1964.03060300069031